Baseline TT2 patient characteristics according to TP53 expression level
| Characteristic . | Low TP53, % (n = 36) . | High TP53, % (n = 315) . | P† . |
|---|---|---|---|
| Age at least 65 y | 29 | 22 | NS |
| Female sex | 51 | 42 | NS |
| White race | 94 | 88 | NS |
| IgA isotype | 20 | 26 | NS |
| Creatinine at least 2.0 mg/dL (221 μmol/L) | 20 | 10 | NS |
| MRI focal bone lesions, at least 3 | 77 | 55 | NS |
| CRP at least 8.0 mg/L | 49 | 34 | NS |
| LDH at least 190 IU/L | 49 | 31 | .036 |
| β2-microglobulin | |||
| Less than 3.5 mg/L | 60 | 59 | |
| At least 3.5 and less than 5.5 mg/L | 14 | 20 | |
| 5.5 mg/L or more | 26 | 21 | NS |
| Albumin less than 3.5 g/dl | 17 | 14 | NS |
| Hemoglobin less than 10 g/dL | 23 | 26 | NS |
| Bone marrow plasma cells (by aspiration) 33% or greater | 61 | 66 | NS |
| Chromosomal abnormalities (defined by G-banding) | 40 | 34 | NS |
| Deletion of chromosome 13 | 84 | 46 | < .001 |
| Amplification of 1q21 | 75 | 42 | .002 |
| High-risk model (17-gene)* | 19 | 14 | NS |
| Subgroups with poor prognosis* (Proliferation/MMSET/FGFR3/MAF/MAFB) | 59 | 35 | .023 |
| Characteristic . | Low TP53, % (n = 36) . | High TP53, % (n = 315) . | P† . |
|---|---|---|---|
| Age at least 65 y | 29 | 22 | NS |
| Female sex | 51 | 42 | NS |
| White race | 94 | 88 | NS |
| IgA isotype | 20 | 26 | NS |
| Creatinine at least 2.0 mg/dL (221 μmol/L) | 20 | 10 | NS |
| MRI focal bone lesions, at least 3 | 77 | 55 | NS |
| CRP at least 8.0 mg/L | 49 | 34 | NS |
| LDH at least 190 IU/L | 49 | 31 | .036 |
| β2-microglobulin | |||
| Less than 3.5 mg/L | 60 | 59 | |
| At least 3.5 and less than 5.5 mg/L | 14 | 20 | |
| 5.5 mg/L or more | 26 | 21 | NS |
| Albumin less than 3.5 g/dl | 17 | 14 | NS |
| Hemoglobin less than 10 g/dL | 23 | 26 | NS |
| Bone marrow plasma cells (by aspiration) 33% or greater | 61 | 66 | NS |
| Chromosomal abnormalities (defined by G-banding) | 40 | 34 | NS |
| Deletion of chromosome 13 | 84 | 46 | < .001 |
| Amplification of 1q21 | 75 | 42 | .002 |
| High-risk model (17-gene)* | 19 | 14 | NS |
| Subgroups with poor prognosis* (Proliferation/MMSET/FGFR3/MAF/MAFB) | 59 | 35 | .023 |
MRI indicates magnetic resonance imaging; CRP, C-reactive protein; LDH, lactate dehydrogenase; and NS, not significant.
High-risk model1 and PR/MS/MF subgroup designation25 have been described elsewhere.
χ2 was used to compare the clinical and biologic parameters between cases with the lowest 10% of TP53 expression and the other 90% of cases with higher expression levels.